SLC5A2 and Hyperglycemia: The randomized controlled trials demonstrated that careful treatment of hyperglycemia, multifactorial management of risk factors, and new treatment agents, such as SGLT2 inhibitors and GLP1-RA, significantly improve the cardiovascular outcomes (18).